Class 1.1 new drug of Zhejiang medicine, nanofloxacin malate, entered the site for inspection this month
-
Last Update: 2015-03-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to information on CFDA's website, Zhejiang Pharmaceutical (600216 SH) will enter the drug registration and production site for inspection this month According to the drug review process, the product is expected to be approved within half a year It is worth mentioning that ninofloxacin has passed the expert review in September last year The company's personnel confirmed to big smart news agency that the review feedback is optimistic and the important obstacles to approval have been removed Nanofloxacin is a new type of fluoroquinolones free drug and a high-end product of quinolones It has attracted market attention since its application It is generally believed in the industry that ninofloxacin will form a benign complementary advantage with the existing quinolones and antibiotic resistant products of Zhejiang Pharmaceutical, enrich the company's high-end antibiotic product group, improve and enrich the preparation varieties, and improve the current predicament of the decline in API revenue.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
